Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Neovascularization Clear all
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

NCT03953079
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 30, 2026, 5:28 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567
View directory record Official record
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
52
States / cities
Gilbert, Arizona • Encino, California • Mountain View, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

NCT00373659
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 30, 2026, 5:28 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

NCT00492284
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
verteporfin, ranibizumab, dexamethasone
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

NCT03249740
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 30, 2026, 5:28 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

NCT02599064
View directory record Official record
Conditions
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

NCT01255462
View directory record Official record
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 30, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

NCT01122511
View directory record Official record
Conditions
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Interventions
700 ug dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 30, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

NCT00395057
View directory record Official record
Conditions
Choroid Neovascularization, Age-Related Macular Degeneration
Interventions
AGN 211745, Ranibizumab 500µg
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 30, 2026, 5:28 PM EDT
Completed No phase listed Observational

Computer-based Screening for Diabetic Retinopathy

NCT01614327
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
VisionQuest Biomedical LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
19,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

NCT00612456
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 30, 2026, 5:28 PM EDT
Terminated Phase 3 Interventional

A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration

NCT00139282
View directory record Official record
Conditions
"Wet" Age-Related Macular Degeneration
Interventions
Squalamine Lactate
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
Beverly Hills, California • Louisville, Colorado • Boynton Beach, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Oct 30, 2026, 5:28 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, bevacizumab or aflibercept, E10030 sham injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
100
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

NCT00457067
View directory record Official record
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 5:28 PM EDT
Completed No phase listed Observational

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

NCT01880788
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
30 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

NCT00511706
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 30, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Propranolol for Diabetic Retinopathy

NCT01535495
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Propranolol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 30, 2026, 5:28 PM EDT